Startupticker.ch’s Post

#investment I We're proud to share that we have joined a CHF 20M Series C extension of Memo Therapeutics AG bringing the total amount raised in the funding round to CHF 45 million. Ysios Capital and Kurma Partners participated in the extension round, joining existing Series C round investors including Pureos Bioventures, Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, FRESENIUS MEDICAL CARE VENTURES, LLC and redalpine 🎯 Developing best-in-class therapeutic #antibodies to transform the lives of patients with #viral #infections and #cancer. 💼 Thomas Harth , Laura Argelich 💰 Funding will be used to bolster the clinical advancement of Memo Therapeutics lead asset, AntiBKV, expanding the Phase II trial with a dose evaluation extension to be the largest BK viremia therapeutic study ever conducted in kidney transplant recipients 🔬 Lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat #BKvirus infection in #kidney #transplant recipients. This infection can lead to #nephropathy, loss of kidney function, as well as organ failure and rejection. 💥 We believe Memo Therapeutics has developed a very powerful antibody that can address the growing concern of BKV infections in kidney transplant recipients. By being able to preserve the kidney and ensure graft outcome, this antibody could offer a tremendous benefit to patients. 💪 https://lnkd.in/dAPQ_2V9 #vc #biotech #innovation #impactinvesting  #ClinicalTrial #BiotechInvestment #HealthcareInnovation #TransplantCare #VentureCapital #AntibodyDiscovery #InfectiousDiseases #DrugDiscovery #Investing

𝗠𝗲𝗺𝗼 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝘀 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 #𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴 𝘁𝗼 𝗖𝗛𝗙 𝟰𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻: Memo Therapeutics AG (or “MTx”) announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. The new funding will be used to bolster the clinical advancement of MTx’s lead asset, AntiBKV, expanding the Phase II trial with a dose evaluation extension to be the largest BK viremia therapeutic study ever conducted in kidney transplant recipients. The disease represents a potential market in excess of $1 billion and is caused by the BK virus, which can become reactivated in immunosuppressed kidney transplant patients leading to severe complications. Initial data from the Phase II trial is expected in the first half of 2025. 𝗣𝗿𝗼𝗰𝗲𝗲𝗱𝘀 𝘄𝗶𝗹𝗹 𝗯𝗲 𝘂𝘀𝗲𝗱 𝘁𝗼 𝗲𝘅𝗽𝗮𝗻𝗱 𝗣𝗵𝗮𝘀𝗲 𝗜𝗜 𝗼𝗳 𝗯𝗲𝘀𝘁-𝗶𝗻-𝗰𝗹𝗮𝘀𝘀 𝗮𝗻𝘁𝗶-𝗕𝗞 𝗩𝗶𝗿𝘂𝘀 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝘁𝗼 𝗯𝗲𝗰𝗼𝗺𝗲 𝘁𝗵𝗲 𝗹𝗮𝗿𝗴𝗲𝘀𝘁 𝘀𝘁𝘂𝗱𝘆 𝗲𝘃𝗲𝗿 𝗰𝗼𝗻𝗱𝘂𝗰𝘁𝗲𝗱 𝗳𝗼𝗿 𝗕𝗞 𝘃𝗶𝗿𝘂𝘀 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗶𝗻 𝗸𝗶𝗱𝗻𝗲𝘆 𝘁𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/eG8yNE7X Erik van den Berg, Thomas Harth, Hadrien Bouchez

Tremendous news from Orthogon Therapeutics, Pledge Therapeutics antiviral arm: We are celebrating a major technical milestone and securing an additional $6M for our pioneering drug to combat #BKvirus! Our lead molecule completed acute toxicity studies, unlocking $3M from dedicated healthcare investors, wrapping up a $6M financing over the past year, bringing the total raised to $18.5M! A groundbreaking journey lies ahead of us, and we're thrilled to forge ahead in search of a transformative solution for kidney transplant patients: #BKvirus is a type of polyomavirus that causes a lifelong, persistent, and often asymptomatic infection in over 80% of healthy adults. In transplant patients, nearly half experience BK virus reactivation in their kidneys, which can lead to serious complications and loss of the transplanted organ. #AntiviralTherapeutics #MedicalInnovation #BKvirusTreatment #HealthcareAdvancements https://lnkd.in/gBkAgj2r

Kidney Awareness Month during March is a particularly meaningful time for us here at Memo Therapeutics, given the many challenges facing Chronic Kidney Disease (#CKD) patients, especially those needing kidney transplantation. With approximately 500,000 people requiring end stage renal disease dialysis support and 100,000 people waiting for kidney transplants in the US alone, early diagnosis and pre-emptive treatment could save thousands of patients’ lives and preserve the quality of life for many others. At Memo Therapeutics, we have used our innovative antibody discovery platform to develop a monoclonal antibody, now in Phase II clinical development, to target BK virus: a major contributor to post-transplantation complications and ultimately graft loss. Read more about our program here:  https://lnkd.in/en6ZhHbV #KidneyAwarenessMonth #KidneyHealth #TransplantsforAll #MemoTherapeutics #MTx #Biotech #AntibodyDiscovery #InfectiousDiseases #DrugDiscovery  

Tremendous news from Orthogon Therapeutics, Pledge Therapeutics antiviral arm: We are celebrating a major technical milestone and securing an additional $6M for our pioneering drug to combat #BKvirus! Our lead molecule completed acute toxicity studies, unlocking $3M from dedicated healthcare investors, wrapping up a $6M financing over the past year, bringing the total raised to $18.5M! A groundbreaking journey lies ahead of us, and we're thrilled to forge ahead in search of a transformative solution for kidney transplant patients: #BKvirus is a type of polyomavirus that causes a lifelong, persistent, and often asymptomatic infection in over 80% of healthy adults. In transplant patients, nearly half experience BK virus reactivation in their kidneys, which can lead to serious complications and loss of the transplanted organ. #AntiviralTherapeutics #MedicalInnovation #BKvirusTreatment #HealthcareAdvancements https://lnkd.in/enEXPeKF

📣 Kudos to Orthogon Therapeutics, our antiviral arm at Pledge Therapeutics! 🎉 Major technical milestone achieved: our lead molecule completed acute toxicity studies, unlocking $3M, bringing the total raised to $18.5M!    "Our team's unwavering efforts and ingenuity have led us to these important wins. These achievements bring us one step closer to delivering the first-ever treatment for #BKvirus." said Dr. Ali Munawar of Orthogon Therapeutics.   #BKvirus is a type of polyomavirus that causes a lifelong, persistent, and often asymptomatic infection in over 80% of healthy adults. In transplant patients, nearly half experience BK virus reactivation in their kidneys, which can lead to serious complications and loss of the transplanted organ. Proud to be part of this team and journey! #AntiviralTherapeutics #Antiviral #BKvirusTreatment #HealthcareAdvancements    https://lnkd.in/eyXPt_cN

Evvolve Partners with APRINOIA Therapeutics for Capital Raise to Revolutionize Neurodegenerative Disease Management Hamburg, Germany - Evvolve, a capital raising firm specializing in healthcare, AI, technology, and growth sectors, has partnered with APRINOIA Therapeutics, a company dedicated to transforming neurodegenerative disease management. APRINOIA Therapeutics offers next-generation diagnostic tools and targeted therapeutics for patients with neurodegenerative diseases, aiming to improve early diagnosis, track disease progression, and address the root causes of these conditions. Through this collaboration, Evvolve will leverage its investor network and capital raising expertise to fuel APRINOIA Therapeutics' groundbreaking initiatives. "APRINOIA Therapeutics is pioneering a revolution in the early diagnosis and treatment of neurodegenerative diseases," said Vincent, Evvolve's Founder. "We are thrilled to join forces with a company that epitomises innovation and compassion, aligning perfectly with our mission." Jamal Chraibi, Evvolve's Chief Operating Officer, added, "APRINOIA Therapeutics' commitment to advancing diagnostics and therapeutics for neurodegenerative diseases is truly inspiring. This partnership underscores our belief in APRINOIA's potential to revolutionize the field and deliver hope to patients and families affected by these devastating conditions."

Are we to expect completely new mechanism of action compound added to the standard of care in the 1st line treatment of patients with unresectable or metastatic hepatocellular carcinoma (#HCC)? Tempest Therapeutics just announced very good results from ongoing global randomized Phase 1b/2 clinical study (NCT04524871) in which #Amezalpat, a Peroxisome Proliferator-Activated Receptor alpha (#PPARα) antagonist, delivered a six-month improvement in median overall survival (OS) advantage when combined with standard #Atezolizumab and #Bevacizumab in a comparison to #Atezolizumab and #Bevacizumab alone in the first-line treatment of patients with unresectable or metastatic HCC of 21 months vs. 15 months. Besides impressive efficacy across HCC patient subpopulations (including PDL-1 positive and negative population), safety profile of the triplet seems encouraging with no significant additional safety signals observable as added from Amezalpat or Amelzapat disrupting dosing of standard of care. This early data obtained in 70 patient trial is great news for HCC patients if pivotal trial ultimately supports these findings. #HCC #1st line treatment #OS #PD(L)-1 defined population #HCC Etiology #Biotech #clinical oncology https://lnkd.in/gy9nAgMV

🎯 Targeting of LNPs and liposomes to myeloid cells? 🤷♀️ Is it possible? 👇 Check out 👇 Happy to announce a presentation by Daryl Drummond from Akagera Medicines, Inc at our upcoming #PLSymposium2024: 🗓 September 9-11, 2024 🌍 Heidelberg, Germany 🎯 Register: https://lnkd.in/emZgWsuf Targeting of lipid nanoparticles (#LNPs) and #liposomes to #myeloid cells for development of highly efficacious therapeutics and #vaccines against difficult to treat infectious diseases. What it's all about: The targeting of macrophages, monocytes, and dendritic cells with lipidic delivery systems has provided significant promise in the treatment and prevention of disease. The targeting of #tumor-associated macrophages (#TAM) with a highly stabilized and minimally PEGylated liposomal irinotecan gave rise to a highly effective and safe treatment option for patients with metastatic pancreatic #cancer, initially in the second line setting and more recently with positive Phase III clinical data in the front-line setting, making it one of the few treatment options available for this difficult to treat cancer. Join our symposium to learn more! #symposium #industry #conference #pharma

Announcement: New Pitching Start-ups at Global Investor Forum! 🚀   We're excited that Safia K. Rizvi of Cila Therapeutics will be pitching at Global Investor Forum! ✨   About CILA Therapeutics:  CILA THERAPEUTICS is dedicated to respiratory health and focused on innovative treatments to help patients breathe easily and protect their lungs from irreversible damage. They own 100% of the robust IP portfolio that will generate value for investors and patients through the development of:    1. First-in-class, novel, inhaled therapeutics (de-risked) for the treatment of Airway Obstructive Pulmonary Diseases (AOPD) including COPD, Bronchiectasis, severe Asthma, Cystic fibrosis, and more.   2. A co-therapy platform to improve (3X) the transfection efficiency of nucleic acid therapeutics (RNA, DNA) delivery, increasing the efficacy and safety of these therapeutics for lung diseases, including lung cancer.    Read more about Safia K. Rizvi & CILA Therapeutics here: https://lnkd.in/eVMNZRBG   👏 Join us: Are you a start-up wanted to pitch your company for investors and other key players in the industry? Or are you an investor looking to meet innovative companies? Join us at I4H Global Investor Forum.   Save the date 🗓️ 27 March 2024 📍Loyens & Loeff office Rotterdam 🔗https://lnkd.in/gFNMW3HE